There are several reasons behind the decision to merge the two companies:
The merged company will be named “Oncology Venture A/S”.
Nasdaq First North in Stockholm
You will keep the same number of shares as you have now. The ticker and company name of the shares will change on Monday 3 September 2018 (to Oncology Venture A/S, OV.ST)
For each share in Oncology Venture Sweden AB, you’ll received 1.8524 shares in the merged entity, shares are expected to be distributed in deposits on 11 September 2018. Cash payments following the sale of fractional shares are expected to be distributed to the entitled recipients on or around September 12, 2018.
Cost synergies will be realized, as overlapping activities will be eliminated. These will come from reduced costs related to having one listed entity instead of two, fewer costs related to auditing, administration etc.
From 3 September it will only be possible to buy shares in “Oncology Venture A/S”, ticker: OV.ST.
The merged company will have a range of assets.
Oncology Venture’s universal Patient Response Predictor (PRP®), a tool which can guide doctors and patients in the process of selecting cancer drugs with a high likelihood of efficacy. The tool is currently in development phase, and the company has proven the PRP’s ability to predict, whether treatment with a range of widely used cancer drugs would be likely to benefit specific patients (or not).
Oncology Venture | Venlighedsvej 1 | DK-2970 | Hørsholm | Denmark | CVR: 3462 3562 | Phone +45 21 70 10 49